This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Facial Plastic Surgery  • Cosmetic Surgery/ Procedures  • Randomized Controlled Trial  • Dermatologic Disorders, Other  • Drug Therapy  • Alert me on articles by topic

Syrus Karsai, MD; Robert Adrian, MD; Stefan Hammes, MD; Jürgen Thimm, MD; Christian Raulin, MD, PhD

Arch Dermatol. 2007;143(11):1447-1449.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The difference between the potency units of the 2 main botulinum toxin A products, Botox (Allergan, Irvine, California) and Dysport/Reloxin (Ipsen Ltd, Slough, England), is still a subject of discussion even after 15 years of clinical use. The manufacturer of Botox recommends higher ratios than does the manufacturer of Dysport/Reloxin. Herein, we report the findings of a randomized, double-blind, split-face study of forehead wrinkles and electromyographic (EMG) activity following application of the 2 products at a 3:1 dose ratio, independent of the support of either manufacturer.

Methods

Patients included in the study were aged 30 to 70 years, had moderate to severe hyperfunctional forehead wrinkles at rest and maximum contraction, and gave written informed consent. The study was approved by the institution's human research review committee.

Twenty-six patients were enrolled, 2 of whom were lost . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION